Belite Bio gains on China nod for lead drug trial

Belite Bio

16/09/2022 14:48

** Shares of drug developer Belite Bio Inc  BLTE.O  rise as
much as 3% to $36.64
    ** Company says received approval from Chinese health
regulator to begin late-stage study of LBS-008 in adolescents
with Stargardt disease in China  urn:newsml:reuters.com:*:nGNX5T02gv
    ** Stargardt disease is a rare genetic eye disorder which
causes progressive vision loss
    ** Company is testing LBS-008 in a mid-stage study and a
global late-stage study in adolescent patients with the disease
    ** BLTE says prelim data from mid-stage trial shows 8 of 13
patients showed improved clarity of vision in at least one eye
at six-month interval 
    ** LBS-008 has received "fast track" and "orphan drug" tags
in the U.S. for Stargardt disease 
    ** As of last close, BLTE shares up more than 3x since
Nasdaq debut in April

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788))